Skbloom

https://www.mayoclinic.org/diseases-conditions/psoriasis/diagnosis-treatment/drc-20355845

Psoriasis - Diagnosis and treatment - Mayo Clinic

May 17, 2024 ... Psoriasis treatments aim to stop skin cells from growing so quickly and to remove scales. Options include creams and ointments (topical therapy), light therapy ...

WebMD

https://www.webmd.com/skin-problems-and-treatments/psoriasis/research

The Best New Medications & Treatments for Psoriasis

Jan 10, 2023 ... Deucravacitinib (Sotyktu) is a medication approved to treat moderate-to-severe plaque psoriasis. A first-in-class, oral, selective, allosteric ...

The New England Journal of Medicine

https://www.nejm.org/doi/full/10.1056/NEJMoa2102383

Bimekizumab versus Secukinumab in Plaque Psoriasis | New ...

Apr 23, 2021 ... Treatment with bimekizumab resulted in greater skin clearance than treatment with secukinumab over 16 and 48 weeks but was associated with oral candidiasis.

WebMD

https://www.webmd.com/skin-problems-and-treatments/psoriasis/systemic

Advanced Psoriasis Treatment: When Topical Creams Aren't Enough

Jul 20, 2023 ... Biologic therapies, including adalimumab (Humira), brodalumab (Siliq), certolizumab pegol (Cimzia), etanercept (Enbrel), guselkumab (Tremfya), ...

The New England Journal of Medicine

https://www.nejm.org/doi/full/10.1056/NEJMoa1512711

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Jun 8, 2016 ... Advances in understanding the pathogenic cytokine network of psoriasis have led to the development of new treatments that provide greater ...

https://news.bms.com/news/details/2022/New-Two-Year-Deucravacitinib-Data-Reinforce-Durable-Efficacy-and-Consistent-Safety-Profile-in-Treatment-of-Moderate-to-Severe-Plaque-Psoriasis/default.aspx

New Two-Year Deucravacitinib Data ... - Bristol Myers Squibb

May 12, 2022 ... Results add to the growing body of evidence on deucravacitinib, a potential new oral treatment option for moderate to severe plaque psoriasis.

PubMed Central (PMC)

https://pmc.ncbi.nlm.nih.gov/articles/PMC8258237/

Latest Advances for the Treatment of Chronic Plaque Psoriasis with ...

Jun 29, 2021 ... Original articles investigating emerging biological, small oral molecules and new biosimilars for chronic plaque psoriasis at phase III stage of ...

PubMed

https://pubmed.ncbi.nlm.nih.gov/26692125/

A new therapeutic for the treatment of moderate-to-severe plaque ...

Psoriasis is a common, chronic, inflammatory skin disease. Being a life-long condition, a prolonged and safe control of the disease is needed.

PubMed Central (PMC)

https://pmc.ncbi.nlm.nih.gov/articles/PMC7042876/

Comparison of Biologics and Oral Treatments for Plaque Psoriasis ...

Feb 5, 2020 ... Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):pii:E2297. doi: 10.3390/ijms18112297 [DOI] [PMC free article] ...

Drugs.com

https://www.drugs.com/medical-answers/new-drugs-treatment-plaque-psoriasis-3511670/

What are the new drugs for plaque psoriasis?

Official answer: The newest systemic treatment for plaque psoriasis is the interleukin-17A and interleukin-17F antagonist bimekizumab...

Recommendation

Recommendation